VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Tuesday, December 30, 2025
Stock Comparison
DSM-Firmenich AG vs Gilead Sciences, Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
DSM-Firmenich AG
DSFIR · Euronext Amsterdam
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into DSM-Firmenich AG's moat claims, evidence, and risks.
View DSFIR analysisGilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 63 / 100 for DSM-Firmenich AG).
- Segment focus: DSM-Firmenich AG has 4 segments (31% in Perfumery & Beauty); Gilead Sciences, Inc. has 5 segments (68.5% in HIV).
- Moat breadth: DSM-Firmenich AG has 10 moat types across 4 domains; Gilead Sciences, Inc. has 8 across 3.
Primary market context
DSM-Firmenich AG
Perfumery & Beauty
B2B fragrances, perfumery ingredients, and beauty ingredients
Global
Consumer brands (fine fragrance, personal care, home care) and beauty brands
Ingredient supplier / fragrance house (co-creation + ingredient palette)
31%
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
Side-by-side metrics
Moat coverage
Shared moat types
DSM-Firmenich AG strengths
Gilead Sciences, Inc. strengths
Segment mix
DSM-Firmenich AG segments
Full profile >Perfumery & Beauty
Oligopoly
Taste, Texture & Health
Oligopoly
Health, Nutrition & Care
Competitive
Animal Nutrition & Health
Competitive
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.